The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis

Comparative Hepatology

Volumn 4, Issue , 2005, Pages

  Poynard, Thierry ^a   Ratziu, Vlad ^a   Naveau, Sylvie ^b   Thabut, Dominique ^a   Charlotte, Frederic ^a   Messous, Djamila ^a   Capron, Dominique ^b   Abella, Annie ^b   Massard, Julien ^a   Ngo, Yen ^a   Munteanu, Mona ^c   Mercadier, Anne ^a   Manns, Michael ^d   Albrecht, Janice ^e  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b HÔPITAL ANTOINE BÉCLÈRE   (France)

^c Biopredictive   (France)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA 2 MACROGLOBULIN; APOLIPOPROTEIN A1; BILIRUBIN; BIOLOGICAL MARKER; CHOLESTEROL; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HAPTOGLOBIN; TRIACYLGLYCEROL;

ADULT; ALCOHOL LIVER DISEASE; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CHRONIC LIVER DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEVICE; DIAGNOSTIC VALUE; DISEASE SEVERITY; FATTY LIVER; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; METABOLISM; NONALCOHOLIC FATTY LIVER; PREDICTION; QUANTITATIVE DIAGNOSIS; RISK FACTOR; SCORING SYSTEM;

EID: 30044437451     PISSN: 14765926     EISSN: 14765926     Source Type: Journal    
DOI: 10.1186/1476-5926-4-10     Document Type: Article

References (50)

1. McCullough AJ: The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis 2004, 8:521-33.
2. Clark JM, Brancati FL, Diehl AM: The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003, 98:960-967.
3. Bellentani S, Saccoccio G, Masutti F, Croce LS, Brandi G, Sasso F, Cristanini G, Tiribelli C: Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000, 132:112-7.
4. Levitsky J, Mailliard ME: Diagnosis and therapy of alcoholic liver disease. Semin Liver Dis 2004, 24:233-47.
5. Day CP: Pathogenesis of steatohepatitis. Best Pract Res Clin Gastroenterol 2002, 16:663-678.
6. Browning JD, Horton JD: Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004, 114:147-152.
7. Wanless IR, Shiota K: The pathogenesis of nonalcoholic steatohepatitis and other fatty liver diseases: a four-step model including the role of lipid release and hepatic venular obstruction in the progression to cirrhosis. Semin Liver Dis 2004, 24:99-106.
8. El-Serag HB, Tran T, Everhart JE: Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004, 126:460-468.
9. Dam-Larsen S, Franzmann M, Andersen IB, Christoffersen P, Jensen LB, Sorensen TI, Becker U, Bendtsen F: Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut 2004, 53:750-755.
10. Sorensen TI, Orholm M, Bentsen KD, Hoybye G, Eghoje K, Christoffersen P: Prospective evaluation of alcohol abuse and alcoholic liver injury in men as predictors of development of cirrhosis. Lancet 1984, 2:241-244.
11. Teli MR, Day CP, Burt AD, Bennett MK, James OF: Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. Lancet 1995, 346:987-990.
12. Fabris P, Floreani A, Carlotto A, Giordani MT, Baldo V, Stecca C, Marchioro L, Tramarin A, Bertin T, Negro F, de Lalla F: Alcohol is an important co-factor for both steatosis and fibrosis in Northern Italian patients with chronic hepatitis C. J Hepatol 2004, 41:644-651.
13. Phillips MJ, Cameron R, Flowers MA, Blendis LM, Greig PD, Wanless I, Sherman M, Superina R, Langer B, Levy GA: Post-transplant recurrent hepatitis B viral liver disease. Viral-burden, steatoviral, and fibroviral hepatitis B. Am J Pathol 1992, 140:1295-308.
14. Bravo AA, Sheth SG, Chopra S: Liver biopsy. N Engl J Med 2001, 344:495-500.
15. Labayle D, Chaput JC, Albuisson F, Buffet C, Martin E, Etienne, JP: Comparison of the histological lesions in tissue specimens taken from the right and left lobe of the liver in alcoholic liver disease. Gastroenterol Clin Biol 1979, 3:235-240.
16. Maharaj B, Maharaj RJ, Leary WP, Cooppan RM, Naran AD, Pirie D, Pudifin DJ: Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet 1986, 1:523-525.
17. Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, Feng ZZ, Reddy KR, Schiff ER: Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002, 97:2614-2618.
18. Bedossa P, Dargère D, Paradis V: Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003, 38:1449-57.
19. Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, Grimaldi A, Poynard T, for the LIDO Study Group: Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005, 128:1898-1906.
20. Poynard T, Ratziu V, Bedossa P: Appropriateness of liver biopsy. Can J Gastroenterol 2000, 14:543-548.
21. Cadranel JF, Rufat P, Degos F: Practices of liver biopsy in France: Results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 2000, 32:477-481.
22. Afdhal NH: Biopsy or biomarkers: is there a gold standard for diagnosis of liver fibrosis? Clin Chem 2004, 50:1299-1300.
23. Poynard T, Imbert-Bismut F, Munteanu M, Messous D, Myers RP, Thabut D, Ratziu V, Mercadier A, Benhamou Y, Hainque B: Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol 2004, 3:8.
24. Myers RP, Tainturier MH, Ratziu V, Piton A, Thibault V, Imbert-Bismut F, Messous D, Charlotte F, Di Martino V, Benhamou Y, Poynard T: Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol 2003, 39:222-230.
25. Callewaert N, Van Vlierberghe H, Van Hecke A, Laroy W, Delanghe J, Contreras R: Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nature Med 2004, 10:1-6.
26. Naveau S, Raynard B, Ratziu V, Abella A, Françoise Imbert-Bismut F, Messous D, Beuzen F, Capron F, Thabut D, Munteanu M, Chaput JC, Poynard T: The diagnostic value of biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease. Clin Gastroenterol Hepatol 2005, 3:167-174.
27. Ratziu V, Le Calvez S, Imbert-Bismut F, Messous D, Charlotte F, Bonyhay L, Munteanu M, Poynard T: Diagnostic value of biochemical markers (Fibrotest) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. Hepatology 2003, 38:510A.
28. Yao W, Zhao B, Zhao Y, Wang W, Qian G: Ultrasonographic texture analysis of parenchymatous organs by the four-neighborhood-pixels algorithm: clinical experiment. J Ultrasound Med 2001, 20:465-471.
29. Marceau P, Biron S, Hould FS, Marceau S, Simard S, Thung SN, Kral JG: Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab 1999, 84:1513-1517.
30. Papadia FS, Marinari GM, Camerini G, Murelli F, Carlini F, Stabilini C, Scopinaro N: Liver damage in severely obese patients: a clinical-biochemical-morphologic study on 1,000 liver biopsies. Obes Surg 2004, 14:952-958.
31. Loguercio C, De Simone T, D'Auria MV, de Sio I, Federico A, Tuccillo C, Abbatecola AM, Del Vecchio Blanco C: Italian AISF Clinical Group. Non-alcoholic fatty liver disease: a multicentre clinical study by the Italian Association for the Study of the Liver. Dig Liver Dis 2004, 36:398-405.
32. Mathiesen UL, Franzen LE, Aselius H, Resjo M, Jacobsson L, Foberg U, Fryden A, Bodemar G: Increased liver echogenicity at ultrasound examination reflects degree of steatosis but not of fibrosis in asymptomatic patients with mild / moderate abnormalities of liver transaminases. Dig Liver Dis 2002, 34:516-22.
33. Poynard T, Ratziu V, McHutchison J, Manns M, Goodman Z, Zeuzem S, Younossi Z, Albrecht J: Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003, 38:75-85.
34. Mottin CC, Moretto M, Padoin AV, Swarowsky AM, Toneto MG, Glock L, Repetto G: The role of ultrasound in the diagnosis of hepatic steatosis in morbidly obese patients. Obes Surg 2004, 14:635-7.
35. Thomas EL, Hamilton G, Patel N, O'dwyer R, Dore CJ, Goldin RD, Bell JD, Taylor-Robinson SD: Hepatic triglyceride content and its relation to body adiposity: a magnetic resonance imaging and proton magnetic resonance spectroscopy study. Gut 2005, 54:122-7.
36. Shalhub S, Parsee A, Gallagher SF, Haines KL, Willkomm C, Brantley SG, Pinkas H, Saff-Koche L, Murr MM: The importance of routine liver biopsy in diagnosing nonalcoholic steatohepatitis in bariatric patients. Obes Surg 2004, 14:54-59.
37. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC,Grundy SM, Hobbs HH: Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004, 40:1387-1395.
38. Poynard T, Munteanu M, Imbert-Bismut F, Charlotte F, Messous D, Dominique Thabut D, Thibaut V, Benhamou Y, Ratziu V: Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clin Chem 2004, 50:1344-1355.
39. Munteanu M, Messous D, Thabut D, Imbert-Bismut F, Jouys M, Massard J, Piton A, Bonyhay L, Ratziu V, Hainque B, Poynard T: Intra-individual fasting versus postprandial variation of biochemical markers of liver fibrosis (FibroTest) and activity (ActiTest). Comp Hepatol 2004, 3:3.
40. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 1994, 20:15-20.
41. Bedossa P, Poynard T, Naveau S, Martin ED, Agostini H, Chaput JC: Observer variation in assessment of liver biopsies of alcoholic patients. Alcohol Clin Exp Res 1988, 12:173-178.
42. Poynard T, Mathurin P, Lai CL, Guyader D, Poupon R, Tainturier MH, Myers RP, Muntenau M, Ratziu V, Manns M, Vogel A, Capron F, Chedid A, Bedossa P: A comparison of fibrosis progression in chronic liver diseases. J Hepatol 2003, 38:257-265.
43. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR: Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999, 94:2467-2474.
44. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ: Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41:1313-1321.
45. Halfon P, Imbert-Bismut F, Messous D, Antoniotti G, Benchetrit D, Cart-Lamy P, Delaporte G, Doutheau D, Klump T, Sala M, Thibaud D, Trepo E, Thabut D, Myers RP, Poynard T: A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease. Comp Hepatol 2002, 1:3-7.
46. Imbert-Bismut F, Messous D, Thibaut V, Myers RB, Piton A, Thabut D, Devers L, Hainque B, Mercadier A, Poynard T: Intralaboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors. Clin Chem Lab Med 2004, 42:323-333.
47. Hintze JL: NCSS 2003 User Guide. Number Cruncher Statistical Systems 2003 Software NCSS. Kaysville, Utah: NCSS; 2003.
48. DeLong ER, DeLong DM, Clarke-Pearson DL: Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach. Biometrics 1988, 44:837-945.
49. Zhou X-H, McClish DK, Obuchowski, NA: Statistical Methods in Diagnostic Medicine. New York: John Wiley & Sons; 2002.
50. McClish DK: Analyzing a Portion of the ROC Curve. Med Decis Making 1989, 9:190-195.